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four non-DILI implicated in man) were selected for our 
study, which was conducted, for the first time, across multi-
ple laboratories. None of the cell models could distinguish 
faithfully between DILI and non-DILI compounds. Only 
when nominal in vitro concentrations were adjusted for 
in vivo exposure levels were primary human hepatocytes 
(PHH) found to be the most accurate cell model, closely 
followed by HepG2. From a practical perspective, this 
study revealed significant inter-laboratory variation in the 
response of PHH, HepG2 and Upcyte cells, but not Hep-
aRG cells. This variation was also observed to be com-
pound dependent. Interestingly, differences between donors 
(hepatocytes), clones (HepG2) and the effect of cryopreser-
vation (HepaRG and hepatocytes) were less important than 
differences between the cell models per se. In summary, 
these results demonstrate that basic cell health endpoints 
will not predict hepatotoxic risk in simple hepatic cells in 
the absence of pharmacokinetic data and that a multicenter 
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assessment of more sophisticated signals of molecular ini-
tiating events is required to determine whether these cells 
can be incorporated in early safety assessment.
Keywords Pharmaceuticals · Cytotoxicity · Hepatocytes · 
Predictive toxicology · Toxicity · Acute
Introduction
Drug-induced liver injury (DILI) poses a serious issue not 
only for patients and healthcare professionals, but also for 
the pharmaceutical industry and regulatory authorities. This 
is mainly due to the occurrence of human-specific and idi-
osyncratic adverse reactions at the clinical and post-mar-
keting stages, thus leading to the termination of drug devel-
opment, black box warnings or even withdrawal of drugs 
from the market (Bell and Chalasani 2009; Marino et al. 
2001).
In vitro models, such as the human hepatocarcinoma cell 
line HepG2, are widely used across the pharmaceutical and 
chemical industries, as an initial screen to determine the 
likely risk of new chemical entities (NCEs) eliciting DILI 
in man. This is because (1) they can be applied quickly 
to generate reproducible data, (2) they are amenable to 
high-content screening and (3) they are relatively cheap 
and readily available (Gerets et al. 2012; O’Brien et al. 
2006). Although not of human origin, rodent liver-derived 
cell lines and primary hepatocytes (which are more read-
ily available compared with their human counterpart) are 
also routinely used. However, interspecies differences are 
known to have a significant impact on predictivity of DILI 
and non-DILI compounds (Olson et al. 2000). On the other 
hand, primary human hepatocytes (PHH) are not generally 
used in such a first screen as they exhibit inter-individual 
variation, thereby potentially confounding analysis and 
interpretation of intra-study and/or intra-project results 
between different NCEs; they are also expensive to acquire, 
and they undergo significant de-differentiation during cul-
ture (Guillouzo et al. 2007; Madan et al. 2003; Richert 
et al. 2006). However, PHH cultured in vitro are still con-
sidered to be useful in the testing paradigm, as the near-
est representation of the key metabolically active cell of the 
liver.
Since DILI continues to pose significant problems in 
drug development, this suggests that currently used in vitro 
models are not appropriate for effective screening, but a 
comprehensive, multicenter, unbiased assessment to test 
this unequivocally has never been performed. Therefore, 
the Innovative Medicines Initiative (IMI)-funded consor-
tium ‘Mechanism-based Integrated Systems for the Pre-
diction of Drug-Induced Liver Injury’ (MIP-DILI) has 
assessed current in vitro cell models, using an evidence-
based panel of compounds implicated in DILI in man, in 
order to determine whether any of these simple cell mod-
els per se are actually predictive of human DILI. Further-
more, by using a small panel of DILI- and non-DILI-impli-
cated compounds, and basic measures of cell health, we 
were able to monitor reproducibility across different sites, 
thereby ensuring that our data should be more definitive 
than any currently available.
Materials and methods
PHH, HepG2, HepaRG and Upcyte cells (Table 1) in con-
junction with a particular endpoint (referred to as cell mod-
els) were evaluated using harmonized protocols which were 
designed and agreed by all test site participants as detailed 
below, for their ability to predict DILI liability of NCEs. 
For the assessment of each cell model, the same protocol 
was used by all the test sites involved and the supplier and 
product codes of all materials and reagents included. Each 
training compound was sourced by all test sites from the 
same supplier and acquired the same batch/lot number. 
Plasticware and other reagents such as media and media 
supplements were sourced by all the test sites from the sup-
pliers and product codes stated in the protocols; however, 
standardization did not extend to sourcing these items from 
specific batch/lot numbers. To determine inter-laboratory 
variation, several of the cell models (cryopreserved PHH, 
cryopreserved HepaRG, HepG2/ECACC and Upcyte cells) 
were evaluated by at least two test sites (Table 2). Fur-
thermore, a simple experimental protocol was designed 
(Fig. 1) and basic endpoints were chosen for our cell mod-
els, i.e., resorufin and ATP assays for the assessment of cell 
viability, to allow generation of rapid data by the test sites 
involved that could be easily compared.  
Cell culture
The different seeding densities used are the optimal for 
each cell type. Data generated from each cell model was 
first analyzed relative to the corresponding untreated con-
trols and then comparisons were made across the different 
cell models. Donor details for the fresh and cryopreserved 
PHH as well as the Upcyte cells are summarized in Table 3. 
Allocation of PHH donors for each test site is also sum-
marized in Table 3. Pre-qualification for choosing the five 
cryopreserved PHH donors was based on their viability 
13 North Western Hepatobiliary Unit, Aintree University 
Hospital NHS Foundation Trust, Longmoor Lane, 
Liverpool L9 7AL, UK
14 Université de Franche-Comté, EA 4267, 25030 Besançon, 
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post-thawing, ability to adhere to cell culture plates, meta-
bolic profile and material availability to ensure there was 
sufficient supply for the planned experimental work and 
any future studies. Donor demographics were collected as 
summarized in Table 3; however, these were not considered 
a priority during the pre-qualification stage as the aim was 
to select a cohort of the population in an unbiased manner.
Cryopreserved primary human hepatocytes
Cryopreserved PHH from five donors were provided by 
KaLy-Cell (Plobsheim, France). The human biological sam-
ples were sourced ethically and their research use was in 
accord with the terms of the informed consents. The hepato-
cytes were thawed in KLC-Thawing Medium (KLC-TM; 
proprietary medium composition), centrifuged (168×g; 
20 min; room temperature), washed in KLC-Washing 
Medium (KLC-WM; proprietary medium composition; 
100×g; 5 min; room temperature) and resuspended in KLC-
Seeding Medium (KLC-SM; Williams’ Medium E (Life 
Technologies, Paisley, UK) supplemented with 10 % heat-
inactivated fetal calf serum (FCS, Life Technologies, Pais-
ley, UK), 1 µM dexamethasone (Sigma-Aldrich, St. Louis, 
MO, USA), 4 µg/mL insulin [(Life Technologies, Paisley, 
UK) and 10 units penicillin/10 µg streptomycin (Life Tech-
nologies, Paisley, UK)]. Cell number and viability were 
determined by the trypan blue exclusion method, and the 
cells were plated at a seeding density of 70,000 cells/well 
of a KaLy-Cell home-coated type I rat tail collagen (10 µg/
well) 96-well plate. This seeding density has been optimized 
and recommended by KaLy-Cell to achieve ≥80 % conflu-
ence in a 96-well plate format 24 h after plating. The cells 
were allowed to attach for 4–6 h (37 °C; 5 % CO2; 95 % 
air) after which the cells were overlaid with 0.25 mg/mL 
matrigel in KLC-Seeding Medium and left to incubate over-
night (37 °C; 5 % CO2; 95 % air). Cells were used for anal-
ysis if the attachment efficiency was ≥80 %. Serum-free 
KLC-Maintenance Medium (KLC-MM; Hepatocyte Main-
tenance Medium (Lonza, Basel, Switzerland) supplemented 
with 1 µM dexamethasone (Sigma-Aldrich, St. Louis, MO, 
USA), 4 µg/mL insulin (Life Technologies, Paisley, UK) 
and 10 units penicillin/10 µg streptomycin (Life Technolo-
gies, Paisley, UK) was used for compound treatment.
Fresh primary human hepatocytes
Fresh primary human hepatocytes isolated from a different 
donor (UoL49) to the five cryopreserved PHH donors were 
also included in our analysis. A liver resection from donor 
UoL49 was received as surgical waste from Aintree Hospi-
tal, Liverpool, United Kingdom, with full patient consent Ta
bl
e 
1 
 C
el
l t
yp
es
 a
ss
es
se
d 
fo
r 
th
ei
r 
ab
ili
ty
 to
 p
re
di
ct
 D
IL
I
C
el
l t
yp
e
D
es
cr
ip
tio
n
U
se
s 
in
 D
IL
I 
an
d 
he
pa
to
to
xi
ci
ty
 s
cr
ee
ni
ng
R
ef
er
en
ce
s
H
ep
G
2
H
um
an
 h
ep
at
oc
el
lu
la
r 
ca
rc
in
om
a 
ce
ll 
lin
e,
  
lim
ite
d 
m
et
ab
ol
ic
 c
ap
ac
ity
 c
om
pa
re
d 
 
w
ith
 P
H
H
 (
cl
on
e-
de
pe
nd
en
t)
C
om
m
on
ly
 u
se
d 
fo
r 
ea
rl
y 
 
cy
to
to
xi
ci
ty
 s
cr
ee
ni
ng
(G
er
et
s 
et
 a
l. 
20
12
; H
ew
itt
 a
nd
 H
ew
itt
 2
00
4)
H
ep
aR
G
H
um
an
 h
ep
at
oc
ar
ci
no
m
a 
ce
ll 
lin
e,
 c
o-
cu
ltu
re
  
of
 h
ep
at
oc
yt
es
 a
nd
 c
ho
la
ng
io
cy
te
-l
ik
e 
ce
lls
,  
m
et
ab
ol
ic
 c
ap
ac
ity
 c
om
pa
ra
bl
e 
w
ith
 P
H
H
  
w
ith
ou
t d
on
or
 v
ar
ia
tio
n
Po
te
nt
ia
l u
se
 in
 in
 v
itr
o 
dr
ug
  
m
et
ab
ol
is
m
 s
tu
di
es
(A
nt
he
ri
eu
 e
t a
l. 
20
10
; G
ri
po
n 
et
 a
l. 
20
02
; L
am
be
rt
 
et
 a
l. 
20
09
)
Pr
im
ar
y 
 
hu
m
an
 h
ep
at
oc
yt
es
Is
ol
at
ed
 h
um
an
 h
ep
at
oc
yt
es
, g
ol
d 
st
an
da
rd
 in
  
in
 v
itr
o 
te
st
in
g.
 L
im
ita
tio
ns
 in
 a
va
ila
bi
lit
y 
 
an
d 
in
te
r-
in
di
vi
du
al
 v
ar
ia
bi
lit
y
C
on
si
de
re
d 
to
 b
e 
th
e 
go
ld
 s
ta
nd
ar
d 
fo
r 
in
 v
itr
o 
 
dr
ug
 m
et
ab
ol
is
m
 a
nd
 c
yt
ot
ox
ic
ity
 te
st
in
g
(G
ui
llo
uz
o 
et
 a
l. 
20
07
; M
ad
an
 e
t a
l. 
20
03
)
U
pc
yt
e 
he
pa
to
cy
te
s
T
ra
ns
du
ce
d 
hu
m
an
 h
ep
at
oc
yt
es
 w
ith
 g
en
es
 th
at
  
up
re
gu
la
te
 p
ro
lif
er
at
io
n.
 B
as
al
 e
xp
re
ss
io
n 
of
  
m
et
ab
ol
iz
in
g 
en
zy
m
es
 c
om
pa
ra
bl
e 
w
ith
 5
 d
ay
  
cu
ltu
re
 o
f 
PH
H
N
ew
 c
el
l m
od
el
, a
dv
an
ta
ge
 o
f 
‘u
nl
im
ite
d’
  
nu
m
be
r 
of
 c
el
ls
 f
ro
m
 o
ne
 d
on
or
(B
ur
ka
rd
 e
t a
l. 
20
12
)
 Arch Toxicol
1 3
and ethical approval from the relevant authorities (National 
Research Ethics Service REC reference: 11/NW/0327). 
Upon collection, the specimen was immediately trans-
ported to the University of Liverpool, Liverpool, United 
Kingdom, on ice in HEPES-buffered saline [HBS; 10 mM 
Hepes (Sigma-Aldrich, St. Louis, MO, USA), 5 mM KCl 
(Fisher Scientific, Loughborough, UK), 136 mM NaCl 
(Fisher Scientific, Loughborough, UK) and 0.5 % glucose 
(Fisher Scientific, Loughborough, UK)]. Hepatocyte isola-
tion was performed using a 2-step collagenase method as 
Table 2  Participants in the multicenter assessment of the seven cell models
Test site Cell models
Primary human hepatocytes HepaRG HepG2 Upcyte
Fresh Cryopreserved Fresh Cryopreserved ECACC TS
GSK (Hertfordshire, UK) ● ● ●
KaLy-Cell (Plobsheim, France) ●
Merck (Darmstadt, Germany) ● ● ●
Liverpool University (Liverpool, UK) ● ● ●
Sanofi Aventis (Alfortville and Frankfurt 
am Main, Germany)
● ●
Servier (Gidy, France) ● ●
UCB (Braine-l’Alleud, Belgium) ●
D -4 D -1 D 0 D 1 D 2 D 3
dosing dosing dosing
72 h
Cell viability
(ATP & resazurin)
24 h
Cell viability
(ATP & resazurin)
Seeding
HepaRG/Upcytes
Seeding HepG2/PHH
Fig. 1  Cytotoxicity study design. Primary human hepatocytes (cry-
opreserved and fresh), HepG2 (ECACC and TS clones), HepaRG 
(cryopreserved and fresh), and Upcyte cells were seeded on the days 
indicated followed by exposure to the thirteen training compounds 
(Table 4) as detailed in the method section for 24 or 72 h. After com-
pound treatment, cell viability was assessed by measurement of intra-
cellular ATP and resorufin which is the product when resazurin is 
reduced (a measure of cellular metabolism)
Table 3  Cryopreserved and fresh PHH and Upcyte cells donor information
* Tested by all three test sites involved in assessing cryopreserved PHH (GSK, KaLy-Cell, and UoL, please refer to Table 2)
# Tested by KaLy-Cell
§ Tested by UoL
ID Gender Age Ethnicity Pathology Medication
Primary human hepatocytes
Cryopreserved
B17042008* ♀ 69 Caucasian Breast cancer Not available
M1603LT# ♀ 68 Caucasian Colorectal adenocarcinoma Tardyferon, Lercan, Previscan, Contramal, Cétornan
S1100T# ♂ 59 Caucasian Colorectal adenocarcinoma None
S1070T§ ♂ 69 Caucasian Not available Not available
S1099T§ ♀ 56 Caucasian Colorectal adenocarcinoma Levothyrox, Amlodipine, DiffuK, Ogast
Fresh
UoL49 ♂ 66 Caucasian Not available Not available
Upcyte cells
422A ♂ 0 Hispanic Anoxia None
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described previously (LeCluyse et al. 2005). Briefly, blood 
was removed from the liver tissue by blanching through 
perfusion with HBS pre-warmed to 37 °C and subsequently 
digested with 0.25 mg/mL collagenase A/IV (Sigma-
Aldrich, St. Louis, MO, USA) in HBS containing 0.7 mM 
CaCl2 (Fisher Scientific, Loughborough, UK), also pre-
warmed to 37 °C. The capsule was opened and the hepato-
cytes released and collected in cold Williams’ Medium E 
(Sigma-Aldrich, St. Louis, MO, USA). The hepatocytes 
were separated from the undigested tissue remnants with a 
125-μm mesh, washed twice with cold Williams’ Medium 
E by centrifugation (80×g; 5 min; 4 °C), and the hepato-
cytes resuspended in cold complete Williams’ Medium E 
[supplemented with 1 % insulin–transferrin–selenium (Life 
Technologies, Paisley, UK), 2 mM l-glutamine (Sigma-
Aldrich, St. Louis, MO, USA), 100 nM dexamethasone 
(Sigma-Aldrich, St. Louis, MO, USA), and 1 % penicillin/
streptomycin (Sigma-Aldrich, St. Louis, MO, USA)]. Cell 
number and viability were determined using the trypan 
blue exclusion method, and the cells were plated at a seed-
ing density of 100,000 cells/well in a BD Biocoat Collagen 
I 96-well plate (Becton and Dickinson, New Jersey, USA). 
This seeding density was determined to be optimal for 
these cells in a 96-well plate format to achieve ≥80 % con-
fluence 24 h after plating. The cells were allowed to attach 
for 3 h (37 °C; 5 % CO2; 95 % air), the incubation medium 
removed, and the attached cells overlaid with 0.25 mg/mL 
matrigel (Becton and Dickinson, New Jersey, USA) in cold 
complete Williams’ Medium E. The cells were further incu-
bated overnight (37 °C; 5 % CO2; 95 % air) prior to dosing. 
The cell viability after hepatocyte isolation was 97 %, and 
the cells were 85 % confluent 16 h post-plating. Complete 
Williams’ Medium E was serum-free and was also used for 
compound treatment.
Cryopreserved HepaRG cells
Differentiated cryopreserved HepaRG cells were purchased 
from Biopredic International (Saint-Gregoire, France). The 
cells were thawed in Thawing/Plating Medium [Williams’ 
Medium E supplemented with 1 % penicillin/streptomycin, 
1 % l-Glutamine, 10 % FCS and 12.5 % ADD670 cocktail 
(BioPredic International, Saint-Gregoire, France; propri-
etary medium composition)], centrifuged (500×g; 5 min; 
room temperature) and then resuspended in fresh Thawing/
Plating Medium. After the addition of the ADD670 cock-
tail, the final DMSO concentration in the Thawing/Plat-
ing Medium was 0.5 %. Cell number and viability were 
determined by the trypan blue exclusion method, and the 
cells were plated at a seeding density of 72,000 cells/well 
in white/clear bottom 96-well plates (Beckton Dickinson, 
New Jersey, USA). The cells were cultured (37 °C; 5 % 
CO2; 95 % air) for 24 h after which the Thawing/Plating 
Medium was replaced with a specified Tox medium (Wil-
liams’ Medium E supplemented with 1 % penicillin/strep-
tomycin, 1 % l-Glutamine, and 12.5 % ADD650 cocktail 
[Biopredic International, Saint-Gregoire, France, propri-
etary medium composition]). The Tox medium was serum- 
and DMSO-free. Cells were incubated for another 48 h 
without additional medium change and subsequently used 
for experimentation, if the attachment efficiency was at or 
above 85 %. For compound treatment, the Tox medium was 
used.
Fresh HepaRG cells
Undifferentiated HepaRG cells were purchased from 
Biopredic International (Saint-Gregoire, France). For dif-
ferentiation, one vial of cells was thawed and seeded in a 
75-cm2 flask in proliferation medium [Williams’ Medium 
E supplemented with 2 mM l-Glutamine, 10 % fetal calf 
serum and ADD710 cocktail (BioPredic International, 
Saint-Gregoire, France; proprietary medium composi-
tion)]. The proliferation medium did not contain DMSO. 
The cells were allowed to recover and proliferate in culture 
(37 °C; 5 % CO2; 95 % air) for 2 weeks with a medium 
change of every 2–3 days. The proliferation medium was 
then replaced with the differentiation medium [Williams’ 
Medium E supplemented with 2 mM l-Glutamine, 10 % 
fetal calf serum, and ADD720 cocktail (Biopredic Interna-
tional, Saint-Gregoire, France; proprietary medium com-
position)]. After the addition of the ADD720 cocktail, the 
final DMSO concentration in the differentiation medium 
was 1.7 %. The cells were maintained in culture for 
2 weeks (37 °C; 5 % CO2; 95 % air) after which the cells 
have reached a hepatocyte-like morphology. Differenti-
ated cells were harvested and seeded in 96-well plates at a 
density of 72,000 cells/well in differentiation medium. The 
cells were used for the toxicity study 5 days after seed-
ing. For compound treatment, serum- and DMSO-free Tox 
medium was used [Williams’ Medium E supplemented 
with 2 mM l-Glutamine and ADD650 cocktail (Biopredic 
International, Saint-Gregoire, France; proprietary medium 
composition)].
HepG2/ECACC and HepG2/TS cells
A specific clone of HepG2 cells was purchased from the 
European Collection of Cell Cultures (ECACC). The cells 
were cultivated and low passage frozen stocks were gen-
erated and banked by one MIP-DILI partner designated 
as the cell bank. The cells were distributed to the rele-
vant MIP-DILI partners. The HepG2 cells were cultured 
 Arch Toxicol
1 3
in Dulbecco’s Modified Eagle Medium (DMEM; Lonza, 
Basel, Switzerland) supplemented with 10 % FBS (Lonza, 
Basel, Switzerland), 1 % penicillin/streptomycin (Lonza, 
Basel, Switzerland), 1 % l-glutamine (Lonza, Basel, 
Switzerland) and 1 % non-essential amino acids (NEAA; 
Sigma-Aldrich, St. Louis, MO, USA) and passaged upon 
reaching 80 % confluence using Trypsin–EDTA (Lonza, 
Basel, Switzerland). Cell number and viability were 
determined using the trypan blue exclusion method, and 
the cells were plated at a seeding density of 20,000 cells/
well in BD Biocoat Collagen I 96-well plates (Beckton 
Dickinson, New Jersey, USA). The cells were then incu-
bated for 24 h (37 °C; 5 % CO2; 95 % air) prior to com-
pound treatment during which serum-free culture medium 
was used. To determine whether there are differences in 
response between two clones of the same cell type, an 
in-house clone of HepG2 from one test site referred to as 
the HepG2/TS clone was also assessed for its sensitivity 
to the compounds and compared with the HepG2/ECACC 
clone. The same conditions were applied during the cul-
ture of the HepG2/TS cells with the exception of using a 
NucleoCounter (NC-100, Chemometec) for cell counting, 
TrypLE (Life Technologies, Paisley, UK) for passaging, 
and the seeding density being 30,000 cells/well.
Upcyte hepatocytes
Preliminary assessment of two Upcyte hepatocyte donors 
with regards to their sensitivity to a small set of compounds 
was performed prior to the current study and showed no 
significant difference (data not presented). Furthermore, 
despite the infant age of the donor (422A) used in the cur-
rent study, the basal metabolic profile of this donor includ-
ing phase I and II enzyme activities which are crucial in 
the clearance of compounds from the body, as provided 
by the supplier, was not dissimilar to the adult donors. As 
such, the use of donor 422A was ultimately due to the large 
amount of material available to allow for future studies to 
be carried out should the need arise.
Upcyte hepatocytes from donor 422A (Medicyte, Heidel-
berg, Germany) were thawed in Upcyte Thawing Medium 
[Upcyte High Performance Medium (Medicyte, Heidel-
berg, Germany) and 10 % FCS (Fisher Scientific, Paisley, 
UK)]. The cells were then centrifuged (90×g; 5 min; room 
temperature) and resuspended in fresh Upcyte High Per-
formance Medium (Medicyte, Heidelberg, Germany). Cell 
number and viability were determined via the trypan blue 
exclusion method, and the cells were seeded at 18,750 cells/
well in white/clear bottom 96-well plates (Beckton Dickin-
son, New Jersey, USA). After seeding, the cells were incu-
bated for 72 h (37 °C; 5 % CO2; 95 % air) without addi-
tional medium change prior to compound treatment.
Dosing
For this study, DILI compounds are defined as those that 
have been reported to cause hepatotoxicity in man while 
non-DILI compounds have not. Postulated mechanisms 
of hepatotoxicity of the DILI-implicated compounds and 
corresponding references can be found in Table 4. Final 
concentrations used in the cell incubations for all com-
pounds are also detailed in Table 4. The compound con-
centrations used were chosen as representative for each 
compound when conducting an in vitro safety assessment 
study. All stock solutions, except for metformin, were pre-
pared as 200-fold stocks in DMSO (Sigma-Aldrich, St. 
Louis, MO, USA). Stock aliquots were stored at −20 °C 
and only thawed once. Metformin stock solutions were 
prepared as 200-fold stocks in distilled water. Cells were 
dosed either once and exposed for 24 h or once daily over 
a 3-day period for a 72 h exposure. For the repeat dose, the 
old dosing solution was discarded each day and replaced 
with fresh dosing solution to ensure that the compound and 
DMSO concentrations in which the cells were exposed to 
were constant throughout the 72-h period. Dosing solutions 
were prepared fresh every day. To minimize or prevent non-
specific binding to proteins, all media used for dosing did 
not contain serum. Cells were dosed in technical triplicates 
with a final concentration of 0.5 % DMSO. Controls were 
cells treated with 0.5 % DMSO in dosing medium, in the 
absence of compounds.
Resorufin assay
After incubation with the compounds, cell viability was 
determined using a 4.5 mM stock solution of resazurin 
(Sigma-Aldrich, St. Louis, MO, USA) prepared in phos-
phate buffer. This stock solution was added into the cells 
at 10 % of the cell culture volume to give a final concen-
tration of 450 µM resazurin. The cells were incubated for 
1 h (37 °C; 5 % CO2; 95 % air) after which the medium 
samples were transferred into black, flat-bottomed 96-well 
plates. Reduction of the resazurin dye results in the 
highly fluorescent product, resorufin which is measured at 
530–560 nm excitation wavelength and 590 nm emission 
wavelength.
ATP assay
The CellTiter Glo assay kit (Promega, Madison, WI, USA) 
was used to determine the ATP content in the cells after 
exposure to the thirteen compounds for 24 or 72 h. After 
incubation with the compounds, the cells were washed 
twice with PBS and added with fresh PBS and CellTiter 
Glo solution in equal volumes. The cells were placed in a 
plate shaker for 2 min to induce lysis and left to incubate 
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for 10 min at room temperature. The supernatant samples 
were transferred into opaque flat-bottomed 96-well plates 
(Greiner-Bio-One, Frickenhausen, Germany) and the lumi-
nescence measured.
Data analysis
Cell viability was determined as the percentage of the 
fluorescent resorufin after incubation with resazurin in the 
treated cells compared with vehicle control or the percent-
age of ATP detected in the treated cells compared with 
vehicle control. Individual EC50 values from all participants 
were calculated using GraphPad Prism 6 (version 6.03) 
at one partner site. Concentration series for each com-
pound and cell type were log-transformed and fitted with 
a sigmoidal regression function assuming a lower viability 
plateau with increasing compound concentration of 0 and a 
Hill coefficient of −1 using Python and Prism (GraphPad 
Software). Differences between two dilution series were 
computed using F-tests. Differences were considered sig-
nificant when p < 0.05 and, to compensate for biological 
significance, when relative EC50-differences > three-fold. 
‘No fit’ indicates no decrease in viability of at least one 
compound in the respective pairwise comparison. Variabil-
ity coefficients were calculated by dividing the number of 
tests with significantly different responses by the number 
of all pairwise comparisons. Hierarchical clustering was 
performed using Qlucore Omics Explorer 3.1 on mean-cen-
tered sigma-normalized data using maximum linkage. Cor-
relation of ATP and resorufin values was calculated using 
Pearson correlation. Statistical difference between 24 and 
72 h toxicity measurements was computed using a paired 
Table 4  The panel of compounds used in this study (nine implicated in risk of DILI; four without known DILI liability), including concentra-
tions used, and putative mechanism/s of hepatotoxicity in man
Key a reactive metabolites, b mitochondrial dysfunction, c BSEP inhibition, d lysosomal dysfunction, e immune-mediated
Compound Hepatotoxic/ 
non-hepatotoxic
Final dose concentra-
tions (μM)
Therapeutic function(s) Postulated toxic 
mechanisms
References
Amiodarone Hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Antiarrythmic b, d (Bandyopadhyay et al. 
1990; Dake et al. 1985; 
Pourbaix et al. 1985)
Bosentan Hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Antihypertensic c (Fattinger et al. 2001; 
Gutierrez et al. 2013)
Buspirone Non-hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Anxiolytic Non-hepatotoxic (Sakr and Andheria 
2001; Zhu et al. 2005)
Diclofenac Hepatotoxic 10, 30, 50, 100, 300, 
500, 1000
Analgesic a, b, c (Tujios and Fontana 
2011)
Entacapone Non-hepatotoxic 10, 30, 50, 100, 300, 
500, 1000
Parkinson’s disease Non-hepatotoxic (Heikkinen et al. 2001; 
Lautala et al. 2000)
Metformin Non-hepatotoxic 30, 50, 100, 300, 500, 
1000, 3000
Antidiabetic Non-hepatotoxic (Tucker et al. 1981; 
Tzvetkov et al. 2009)
Nefazodone Hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Antidepressant a, c (Barbhaiya et al. 1996; 
Kalgutkar et al. 2005; 
Kostrubsky et al. 2006)
Paracetamol Hepatotoxic 30, 100, 300, 1000, 
3000, 10,000, 30,000
Analgesic a (Dahlin et al. 1984; 
Sevilla-Tirado et al. 
2003)
Perhexiline Hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Antianginal c, d (Amoah et al. 1986; 
Fromenty and Pessayre 
1997)
Pioglitazone Non-hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Antidiabetic Non-hepatotoxic (Rajagopalan et al. 2005; 
Wong et al. 2004)
Tolcapone Hepatotoxic 10, 30, 50, 100, 300, 
500, 1000
Parkinson’s disease a, c (Jorga et al. 1999; Lau-
tala et al. 2000; Smith 
et al. 2003)
Troglitazone Hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Antidiabetic, anti-
inflammatory
a, b, c, d (Kaplowitz 2005; Loi 
et al. 1999; Loi et al. 
1997)
Ximelagatran Hepatotoxic 3, 5, 10, 30, 50, 100, 
300
Anticoagulant e (Keisu and Andersson 
2010; Schutzer et al. 
2004)
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Student’s t test. In order to relate compound concentra-
tions leading to loss of viability to therapeutic concentra-
tions, the EC50 values were divided by the corresponding 
Cmax values (EC50/Cmax). References used to obtain these 
values (µM) are provided in Table 4: amiodarone—0.807; 
nefazodone—0.859; paracetamol—139; tolcapone—27.81; 
diclofenac—7.44; ximelagatran—0.3; troglitazone—6.387; 
perhexiline—1.525; bosentan—7.4; buspirone—0.005; 
entacapone—1.5; metformin—7.74; pioglitazone—2.672.
Results
The primary aim of this study was to determine, in an unbi-
ased fashion, if several simple cell models (defined as a cell 
type in conjunction with a specific endpoint), currently used 
in industry, can distinguish between NCEs with respect to 
their potential to cause DILI in man, in the absence of 
exposure data. Nine compounds that are associated with 
human DILI and four that are not (Table 4) were investi-
gated using four simple cell types: PHH, HepG2, HepaRG 
and Upcyte cells. In order for this study to be conducted 
in a standardized manner across multiple centers in Europe 
(for study scheme and participants, see Fig. 1 and Table 2, 
respectively), two simple endpoints, ATP and resorufin, 
were measured to assess toxicity. Our results demonstrated 
good correlation between these two endpoints for all com-
pounds, time points and cells (r = 0.94, Supplementary 
Table 1); therefore, only ATP data are shown in the figures 
in the main body of the paper, for the sake of clarity.
To assess the primary aim of our study, the EC50 values 
for the ATP response to each of the compounds grouped as 
DILI and non-DILI, by the HepG2/ECACC, cryopreserved 
PHH, cryopreserved HepaRG and Upcyte cells after a 24 h 
and 72 h exposures, are shown in Fig. 2. No clear segre-
gation between the DILI and non-DILI compounds was 
observed based on the EC50 values for each compound per 
cell type demonstrating that none of the cell models were 
able to faithfully distinguish between DILI and non-DILI 
compounds, at either time point.
We then corrected for in vivo exposure by calculating 
EC50 (ATP)/Cmax for each compound in each cell model at 
24 and 72 h (Fig. 3a–f). For clarity, Fig. 3c and d are on 
a linear scale to aid comparisons between the cell models. 
Importantly, while no cell model was able to distinguish 
between DILI- and non-DILI-implicated compounds based 
on primary EC50 values as obtained in the early stages of 
drug development, primary human hepatocytes and, to a 
lesser extent, HepG2 cells can indicate DILI risks when 
exposure levels are accounted for. As no unequivocal criti-
cal EC50/Cmax is defined in the literature, we assessed how 
many DILI compounds were classified as potentially hepa-
totoxic using a range of values (Supplementary Fig. 1). 
With an EC50/Cmax of 20 (Fig. 3e, f), all DILI-implicated 
compounds are recognized as such in PHH after 72 h (but 
not after 24 h), with the exception of ximelagatran, while 
only one of the control compounds falls below the EC50/
Cmax = 20 level (entacapone). With the exception of par-
acetamol, HepG2 cells generated similar profiles to the 
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Fig. 2  Simple-cell models using a basic measure of cell health can-
not discriminate between DILI-implicated and non-DILI-implicated 
compounds. Scattergram of EC50s derived from intracellular ATP con-
tent measurements after exposure to the training compounds of each 
cell type for 24 (a) or 72 h (b), expressed as the mean of multiple 
determinations carried out across all the test sites involved in assess-
ing each cell type
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cryopreserved PHH after exposure to the compounds for 
72 h (Fig. 3d).
We then explored inter- and intra-laboratory variation in 
our data, the effect of inter-donor and clonal variation, as 
well as differences in sensitivity to the compounds between 
fresh and cryopreserved cells. As part of our experimen-
tal design, cryopreserved PHH, HepG2/ECACC, cryo-
preserved HepaRG, and Upcyte cells were evaluated by 
at least two test sites to allow pairwise comparison of the 
cytotoxicity profiles generated (Table 2). For each of the 
cell models evaluated, the statistical significance of all pair-
wise comparisons between cytotoxicity curves was deter-
mined. We detected statistically significant inter-laboratory 
variation in the cytotoxicity profiles generated by each test 
site that assessed cryopreserved PHH, HepG2/ECACC, 
and Upcyte cells for their response to all the training 
compounds. These differences appeared to be of varying 
degrees, while the Upcytes (12.3 %) showed minor vari-
ability between the laboratories, and the HepG2/ECACC 
(23.4 %) and primary human hepatocytes (48.5 %) elicited 
clear variable responses. On the other hand, the HepaRG 
cells showed no difference in all pairwise comparisons per-
formed. Furthermore, the degree in which each compound 
varied per cell type across the relevant test sites also dif-
fered with the exception of ximelagatran, for which no 
toxicity was detected even at the highest doses despite the 
use of harmonized protocols (Fig. 4). As such, the inter-
laboratory differences appeared to be cell type- as well as 
compound-dependent.
Similar to our findings on inter-laboratory variabil-
ity, differing degrees of intra-laboratory variability were 
observed between cell types. In particular, HepG2 (15.4 %) 
and Upcyte (11.5 %) cells differed markedly between rep-
licate experiments in the same laboratory while HepaRG 
(5.7 %) and PHH (2 %) varied considerably less. In addi-
tion, intra-laboratory analysis was also observed to vary 
between compounds ranging from no significant variation 
between replicate experiments observed with paracetamol 
and diclofenac compared with pioglitazone demonstrat-
ing differences in 21.1 % of comparisons. Based on these 
results, we conclude that intra-laboratory variation and thus 
Fig. 3  When Cmax data are available, primary human hepatocytes are 
the most sensitive of the cell models for the assessment of cellular 
toxicity. a, b Clustered column plots showing the EC50/Cmax values 
for all thirteen compounds as detected by all seven forms of the cell 
models assessed after 24 (a) and 72 h (b). The four compounds not 
implicated in DILI are indicated. c, d DILI-implicated compounds 
after 24- (c) and 72-h exposure (d) are shown on a linear axis to aid 
comparisons between the different cell models. e, f Stacked column 
plots visualizing the number of compounds classified as toxic by the 
different cell models with a EC50/Cmax of 20 (red line in panel a) after 
24 (e) and 72 h (f). Note that primary human hepatocytes (PHH) are 
the most sensitive cell type recognizing 8 of the 9 compounds impli-
cated in DILI after 72 h (color figure online)
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result reproducibility can also differ between cell types and 
compounds.
In order to examine differences in compound sensitivity 
between cryopreserved and fresh cells, cryopreserved and 
fresh HepaRG cells were compared in their response to the 
compounds tested (Fig. 5). We observed a biologically sig-
nificant difference between cryopreserved and fresh Hep-
aRG cells for only three compounds. Similarly, we also 
compared the cytotoxicity profiles generated for each of 
the training compounds from one fresh PHH donor with the 
five cryopreserved donors and found a biologically signifi-
cant difference for two compounds (Supplementary Fig. 2).
Differences in basal activities of phases I and II enzymes 
have been reported in HepG2 cells that have been obtained 
from different sources (Hewitt and Hewitt 2004). There-
fore, we determined whether different clones of the same 
cell line vary in their response to chemical insult by com-
paring two clones of HepG2 cells (Fig. 6). The ECACC 
clone is a commercially available HepG2 clone that is used 
by the MIP-DILI consortium for all HepG2-related studies 
for consistency. This allows direct comparison of results 
between studies conducted within the consortium. The 
results indicated differences between the two clones for 
only four of the compounds.
Fig. 4  Degree of inter-laboratory variability depends on the cell 
model and the compound. Stacked column plots demonstrating the 
degree of inter-laboratory variability for HepG2/ecacc (a), Upcyte 
(b), cryopreserved HepaRG cells (c), and cryopreserved PHH (d). 
On the y-axis, the number of different (shades of red) and not dif-
ferent (shades of blue) pairwise comparisons between the participat-
ing partner laboratories is depicted. While HepaRG cells and Upcytes 
(12.3 %) show no or minor variability between laboratories, HepG2/
ecacc (23.4 %) and primary human hepatocytes (48.5 %) elicit vari-
able responses (color figure online)
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Five cryopreserved hepatocyte donors were also 
assessed for inter-donor variability, and the influence of 
inter-donor variation was found to be only minor (8.1 %, 
Fig. 7). Interestingly, hierarchical clustering of the four 
cell types based on the EC50 values derived from the ATP 
measurements demonstrated close clustering between all 
the primary human hepatocyte donors while the HepG2, 
HepaRG and Upcyte cells constitute a second cluster 
(Fig. 8). This analysis further demonstrates the minor 
influence of donor variation between the five donors used 
for cryopreserved PHH in this study, as well as cryopre-
served versus fresh cells (HepaRG and PHH) and clonal 
differences (HepG2).
Discussion
The prediction of drug-induced liver injury (DILI) remains 
a challenge for medical professionals, the pharmaceuti-
cal industry, and regulatory authorities (Chen et al. 2014; 
Marino et al. 2001). We therefore conducted a comprehen-
sive and unbiased acute cytotoxicity assessment of four cell 
models (PHH, HepG2, HepaRG and Upcyte cells, in con-
junction with basic measures of cell health, namely ATP 
and resorufin) that are currently used in industry as part of 
a testing strategy to determine DILI risk. Furthermore, we 
Fig. 5  Fresh and cryopreserved cells elicit overall similar responses 
to the compounds. Stacked column plots showing the responses of 
fresh and cryopreserved HepaRG cells. On the y-axis, the number of 
different (shades of red) and not different (shades of blue) pairwise 
comparisons between fresh and cryopreserved cells are plotted. Dif-
ferences in responses are detected in 18.4 % (HepaRG) of all pair-
wise comparisons (color figure online)
Fig. 6   Comparison of the responses of two commonly used HepG2 
clones indicates only minor differences between clones. Stacked 
column plot showing the differences in response to the compounds 
between HepG2/ecacc and HepG2/TS clones. On the y-axis, the 
number of different (shades of red) and non-different (shades of blue) 
pairwise comparisons is depicted. While responses to amiodarone and 
nefazodone are dissimilar, only few differences in the response to the 
other compounds are detected (overall 16.2 % differences) (color fig-
ure online)
Fig. 7  Inter-donor variability in response to the compounds is neg-
ligible. Stacked column plot visualizing the differences in responses 
of cryopreserved PHH isolated from five different donors. In total, 
differences are only detected in 8.1 % of pairwise comparisons sug-
gesting that responses to chemical insult by the compounds are only 
marginally affected by the genetic background of the donor
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used a multinational multicenter approach, involving six 
industry partners and one academic partner, with the major-
ity of the cell models tested in two or more independent 
sites (Table 2). To our knowledge, this is the first time such 
a study has been done for the types of basic cell models 
that are commonly used in hepatotoxicity studies. Cyto-
toxicity profiles were generated in response to nine human 
DILI-implicated compounds, which were chosen according 
to their proposed mechanisms of hepatotoxicity in human 
liver, and four compounds without known human DILI 
liability (Table 4). Furthermore, other factors relevant in 
safety assessment including clonal differences between cell 
lines, the use of cryopreserved and fresh cells, as well as 
inter-donor variation, were also addressed.
We found that based on the EC50 values obtained from 
this study, none of the four cell models assessed could dis-
tinguish between DILI and non-DILI compounds. This 
is important as it clearly demonstrates, particularly when 
simple endpoints are used—a common approach during 
drug screening—that for the medicinal chemist, none of 
these cell models is suitable for the purpose of predicting 
the likely risk of an NCE to cause DILI in man. Thus, cur-
rent in vitro models must be further developed with respect 
to cell composition as well as endpoints measured in order 
to increase predictability for the various forms of DILI that 
can occur in man. For the simple cell types described here, 
which still retain some significant advantages, e.g., cost, 
availability, and ease-of-use, their utility in safety assess-
ment may be specialized to specific forms of cellular stress, 
e.g., mitochondrial damage, functional changes in endoplas-
mic reticulum, nuclear damage, and lysosomal perturbation, 
many of which are currently used in high-content screens, 
combined with appropriate endpoints. We have recently 
determined the basal hepatic proteome of each of the cell 
types assessed here, data which could be valuable in decid-
ing how these cells are used appropriately (Sison-Young 
et al. 2015). For the current study, this proteomic analysis 
is particularly useful when interpreting the cytotoxicity data 
Fig. 8  Hierarchical clustering separates primay human hepatocytes 
from the assessed cell line culture systems. Cell types were clus-
tered using maximum distance measure based on their mean-centered 
sigma-normalized EC50 values as obtained from ATP measurements. 
Note that while the different primary human hepatocyte donors clus-
ter closely together, HepG2s, HepaRGs, and Upcyte cells constitute a 
second cluster. Coloring indicates deviation from mean
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as it gives an indication of each cell type’s hepatic pheno-
type at the protein level which could be indicative of their 
functional capability. For example, we have demonstrated 
varying protein levels of Phase I and Phase II enzymes in 
each cell type which is an important consideration for the 
current study as several of the compounds tested are known 
to be hepatotoxic through the generation of reactive inter-
mediates (Gustafsson et al. 2014; McGill et al. 2012; Tang 
et al. 1999; Zahno et al. 2011). However, to fully character-
ize each of these cell types, functional measurements would 
have to be performed as one cannot assume that the level of 
abundance of a protein directly correlates with its activity. 
Nevertheless, once we try to go beyond modeling the initial 
chemical insult in the hepatocyte and take account of DILI 
mechanisms including the action of non-parenchymal cells 
as well as blood cells, it is anticipated that either the com-
plexity of in vitro models will have to be increased in order 
to gain higher sensitivity for DILI prediction or more rel-
evant readouts will be needed in order to capture the early 
molecular events and pathways within the hepatocyte which 
eventually lead to DILI as it occurs in a patient. This is par-
ticularly important for compounds such as ximelagatran, in 
which inflammation and the immune system are known to 
play an important role (Edling et al. 2008), and our results 
clearly show that the cell models tested in the current study 
are inadequate for modeling this.
We acknowledge the importance of pharmacokinetic 
data in the development of better models and assessment 
strategies given the central role of the liver in drug disposi-
tion (Smith et al. 2005). As such, Cmax values were factored 
into our analysis, thereby deriving some human exposure 
relevance. Based on this, we found that PHH provided the 
most accurate cell model in distinguishing compounds 
implicated in DILI, reaching detection rates of 89 % after 
72 h (Fig. 3). It is worth pointing out that while the medici-
nal chemist would not generally have Cmax data at an early 
stage in drug development, a predicted therapeutic expo-
sure can be calculated early on in development, and theo-
retically this could be used as a prediction. In the absence 
of known pharmacological Cmax and AUC data, basic cell 
models, as described here, are limited to simple and rapid 
early discovery screens for the ranking of chemical series 
within projects. Therefore, no distinction can be made 
between these cell models regarding sensitivity, selectivity, 
or relevant EC50/Cmax values to predict liver safety, without 
a priori knowledge of the human pharmacokinetic charac-
teristics of the chemical entities per se. We have illustrated 
this by the use of an unbiased panel of DILI and non-DILI 
reference compounds commonly used in industry, and the 
subsequent analysis of cytotoxicity readouts both with and 
without clinical pharmacokinetic data.
The importance of chronic exposure, which is more rep-
resentative of the clinical setting, was clearly evident in the 
current study, as a clear segregation between DILI and non-
DILI compounds in PHH was only observed after a 72-h 
exposure to the training compounds, a pattern that was not 
observed at the 24-h time point. This has also been demon-
strated by Holmgren and colleagues (Holmgren et al. 2014) 
in human stem cell-derived hepatocyte-like cells (HLCs) 
wherein a shift in the cytotoxicity curves of the HLCs after 
a 7 or 14 day exposure to drugs was observed compared 
with HLCs as well as HepG2 cells that have been exposed 
to the same drugs for 48 h. It would therefore be worth-
while in future studies to perform a chronic study in order 
to assess whether each of the cell models tested here can 
better distinguish between DILI and non-DILI compounds 
under chronic rather than acute exposure. In addition to the 
cell models tested in the present study, HLCs are also under 
assessment for their potential as an in vitro tool for predict-
ing DILI risk by several groups in the field (Pradip et al. 
2016; Szkolnicka et al. 2014).
Another aim of this study was to ensure that the data set 
generated was sufficiently robust for use as a reference tool 
for the evaluation of initial markers of chemical insult in 
simple cell models, and to benchmark more complex mod-
els of DILI. Importantly, we detected different degrees of 
inter-laboratory variation across the cell types assessed 
(Fig. 4). The largest inter-laboratory variation was observed 
in the PHH (48.5 %), followed by the HepG2/ECACC cells 
(23.4 %). It is not unexpected that the most complex and 
sophisticated cell in our study, the hepatocyte, shows the 
greatest inter-laboratory variation among the different cell 
models, despite the use of common reagents, plasticware 
and protocols. However, the variation in the HepG2 data 
was surprising particularly as these cells also demonstrated 
the highest level of intra-laboratory variation (11.54 %) 
among all the cell types assessed. Although identical har-
monized protocols for each cell model were used by all 
test sites, our results show differences between laboratories 
that require even more stringent protocols. With the HepG2 
cells, our intra-laboratory data suggests an inherent level of 
variability even within one type of clone. Alternatively, it is 
conceivable that early markers of the initial chemical insult 
would be less variable compared with basic cell health end-
points measured over several days in culture, and would be 
more appropriate (Xu et al. 2004). However, despite these 
variations observed and although none of the cell models 
could faithfully predict DILI risk, the PHH and HepG2 
cells were still relatively accurate in discriminating DILI 
risk when exposure levels are taken into account and that 
this accuracy was not diminished by inter- and intra-labo-
ratory variation.
We also assessed differences between fresh and cryopre-
served HepaRG cells as well as the effect of clonal varia-
tion in the HepG2 cell line. Interestingly, cryopreservation 
had only minor effects on response to chemical insult in 
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the HepaRG cells (Fig. 5). A similar observation was made 
between one donor of fresh and five of cryopreserved PHH 
(Supplementary Fig. 2). As only one donor of fresh PHH 
was used for comparison, additional donors would need 
to be tested in order to make this observation conclusive. 
Nonetheless, our current finding is in agreement with the 
minimal effects of cryopreservation in PHH that has been 
previously reported by other groups (Richert et al. 2006; 
Smith et al. 2012). Also differences between HepG2 clones 
when assessed by one laboratory were found to be of less 
importance (16.3 %, Fig. 6) than inter-laboratory varia-
tions of the same clone (23.4 %, Fig. 4a). The TS HepG2 
clone used to compare with the HepG2/ECACC clone is 
an established HepG2 clone at one of the participating test 
sites and is a cell line that is routinely used for their drug 
screening studies. While this is not a widescale test of all 
HepG2 clones that are available, this does begin to address 
the frequently discussed, but rarely tested, issue of inter-
clonal variation in response to compound exposure.
When inter-donor variation among the PHH was exam-
ined, only 8.1 % of all pairwise comparisons was observed 
to be different (Fig. 7). Furthermore, all five cryopreserved 
PHH donors and one fresh hepatocyte donor were shown 
to cluster together (Fig. 8), suggesting that although donor 
variations were observed in the response of the hepatocytes 
to the compounds, these variations were much less impor-
tant than differences from the other cell models.
In summary, when used with simple endpoints such 
as the measurement of ATP and resorufin, none of the 
cell models currently used in industry (HepG2, HepaRG, 
Upcyte and PHH) can completely distinguish between 
established drugs with respect to their propensity to cause 
DILI in man, and are therefore unlikely to be able to predict 
the DILI hazard and risk for NCEs. However, when in vivo 
exposure levels are taken into account, PHH are the most 
accurate cell model, identifying 8 out of 9 DILI compounds 
as such after 72 h, but not after 24 h of exposure. Our study 
revealed significant inter-laboratory variation for EC50 val-
ues obtained in PHH, HepG2, and Upcyte cells, but not 
in HepaRG cells. Inter-donor and inter-clonal differences 
and the effect of cryopreservation were found to be of 
less importance than differences between the cell models. 
Therefore, while PHH can provide an expedient model to 
aid in the indication of possible DILI risks in later stages 
of drug development, e.g., when in vivo exposure data is 
already available, none of the cell models are suitable to 
indicate the risk of DILI early in drug development. Hence, 
a multicenter assessment of more reliable cell models, i.e., 
simple cell types such as used here, or more complex 3D or 
co-culture models, in conjunction with more sophisticated 
endpoints of molecular initiating events that report on the 
chemical insult in the hepatocyte is needed.
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